FDA Releases Action Plan for Rare Neurodegenerative Diseases, Including ALS
FDA News Release Five-Year Plan Fulfills a Requirement of the Accelerating Access to Critical Therapies for ALS Act For Immediate Release: June 23, 2022 Today, the U.S. Food and Drug Administration unveiled its Action Plan for Rare Neurodegenerative …